Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)65.18
  • Today's Change-0.22 / -0.34%
  • Shares traded868.93k
  • 1 Year change+3.58%
  • Beta1.8666
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CanSino Biologics Inc is a China-based company primarily engaged in the research and development, production, and commercialization of human vaccine products. The Company’s products and product pipeline under research include multiple vaccine varieties such as meningitis, pneumonia, diphtheria, tetanus, and pertussis (DPT), coronavirus disease 2019 (COVID-19), Ebola virus disease, poliomyelitis, herpes zoster, tuberculosis and others. The Company is also engaged in the research and development of pharmaceutical production processes. The Company conducts its business in the domestic and overseas markets.

  • Revenue in CNY (TTM)971.83m
  • Net income in CNY-142.03m
  • Incorporated2009
  • Employees1.11k
  • Location
    CanSino Biologics IncWest District Biomedical Park, No. 185South Avenue, West District, EconomicTIANJIN 300457ChinaCHN
  • Phone+86 2 258213766
  • Fax+86 2 258213626
  • Websitehttps://www.cansinotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Chongqing Genrix Biophrmctcl Co Ltd225.16m-583.52m10.63bn743.00--5.94--47.19-1.59-1.590.61414.880.07120.308810.33303,044.90-18.45---19.95--90.99---259.16--7.37--0.3694--2,384.11--0.5049------
Liaoning Chengda Biotechnology Co Ltd1.47bn177.94m10.79bn1.81k59.811.15--7.340.4330.4333.5622.540.14820.67861.24813,192.101.798.071.868.3679.0384.9812.1135.7519.28--0.001344.77-4.22-0.0082-26.42-13.26-4.72--
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.90bn498.69m10.94bn2.03k21.713.52--5.761.601.606.139.840.34130.93063.06936,748.908.907.1913.049.6766.6459.3026.0820.280.92816.070.460435.8957.2134.33148.1952.7631.58--
Aurisco Pharmaceutical Co Ltd1.62bn424.54m10.98bn1.78k25.564.32--6.761.061.064.076.260.41881.094.41910,578.1010.9411.3712.6013.2959.7752.9326.1322.343.01635.150.280631.5316.8920.4722.5913.7749.45--
Shanghai Yizhong Pharmaceutical Co Ltd247.05m22.96m11.30bn65.00483.127.74--45.750.11320.11321.227.070.1630.95562.263,800,801.001.515.441.585.6481.3992.999.3036.907.84--0.0032.30-51.83---95.68--10.96--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.58bn687.99m11.46bn8.26k16.961.62--1.740.26650.26652.542.800.66172.574.70796,529.007.138.519.6512.7451.8858.6410.7714.121.38--0.053241.54-3.23-0.75945.21--1.57--
Cansino Biologics Inc971.83m-142.03m11.61bn1.11k--3.06--11.95-0.5455-0.54553.9221.370.12710.58611.38879,482.50-1.86-4.08-2.29-5.3878.8045.31-14.62-27.513.29--0.2242--137.01226.4374.45--31.38--
Mayinglong Pharmaceutical Group Co Ltd3.77bn571.60m11.87bn2.65k20.772.76--3.151.331.338.759.970.72116.2311.991,421,812.0011.3810.7713.8213.3546.7742.4015.7814.394.58--0.022637.3118.856.6219.147.9734.4718.98
Jiangxi Tianxin Pharmaceutical Co Ltd2.23bn617.04m12.01bn2.68k19.382.51--5.401.421.425.1110.930.39732.439.65830,883.1011.0117.1011.8821.1643.0442.9927.7230.124.31--0.072124.4117.351.7536.85-2.2035.06--
Chengdu Easton Biopharmaceuticals Co Ltd1.33bn241.37m12.36bn1.52k51.004.31--9.301.371.377.5516.230.38091.835.89873,161.506.928.098.449.8271.9081.7218.1620.103.12--0.044430.3720.827.345.1517.014.24--
Henan Lingrui Pharmaceutical Co., Ltd.3.78bn799.61m12.52bn2.44k15.663.85--3.311.411.416.675.730.7111.898.061,553,625.0015.0811.9025.5218.8979.2674.3621.2116.460.9053--0.137973.975.7210.1727.1919.6714.2924.57
Data as of Feb 11 2026. Currency figures normalised to CanSino Biologics Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

3.67%Per cent of shares held by top holders
HolderShares% Held
China Southern Asset Management Co., Ltd.as of 30 Jun 2025559.13k0.84%
GF Fund Management Co., Ltd.as of 30 Jun 2025488.20k0.73%
China Asset Management Co., Ltd.as of 30 Jun 2025368.87k0.55%
The Vanguard Group, Inc.as of 07 Jan 2026327.12k0.49%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025209.30k0.31%
E Fund Management Co., Ltd.as of 30 Jun 2025112.12k0.17%
China Merchants Fund Management Co., Ltd.as of 30 Jun 2025108.50k0.16%
Guotai Asset Management Co., Ltd.as of 30 Jun 2025104.47k0.16%
Changsheng Fund Management Co., Ltd.as of 30 Jun 202586.74k0.13%
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 202586.73k0.13%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.